Trials / Terminated
TerminatedNCT01351038
Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma
A Two Stage Multicenter Phase II Trial of Concurrent Induction Chemoimmunotherapy With Epirubicine, Oxaliplatin, Capecitabine and Panitumumab in KRAs Wild-type, Resectable Type II Gastric Adenocarcinoma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 43 (estimated)
- Sponsor
- Arbeitsgemeinschaft medikamentoese Tumortherapie · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, multicenter, single-arm phase II trial with primary eqirubicine-oxaliplatin-capecitabine chemotherapy and concurrent Pmab in patients with resectable, histologically proven gastric or esophageal cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Epirubicine, Oxaliplatin, Capecitabine, Panitumumab | 3 cycles (repeated q 21d) Epirubicine 50mg/m² i.v. d1 Oxaliplatin 100mg/m² i.v. d1 Panitumumab 9mg/kg i.v. d1 Capecitabine 500mg/m² bid d1-21 |
Timeline
- First posted
- 2011-05-10
- Last updated
- 2013-06-04
Locations
6 sites across 1 country: Austria
Source: ClinicalTrials.gov record NCT01351038. Inclusion in this directory is not an endorsement.